TC BioPharm Holdings Plc (TCBP)

[ipo_dude]

Dont get sucked in

[ipo_dude]

Yeah !! Cone of uncertainty here ...!!!

[FooBarAndGrill]

Float 0.6M. Could be one whale.

[ipo_dude]

Nothing in these financials to suggest a 80% move

[dinogreeves]

Huge move today.

[TheFinalCD]

TCBP TCBPW financials and update

https://ir.tcbiopharm.com/news/press-releases/detail/43/tc-biopharm-reports-first-half-2022-financial-results-and

https://finviz.com/quote.ashx?t=TCBP&ty=c&ta=1&p=d

On February 15, 2022, the Company announced closing of its $17.5 million Initial Public Offering and began trading on the NASDAQ stock exchange under the ticker "TCBP"

[Pt3]

Pnd

[TheFinalCD]

very unlikely

[TeddyCaswell]

Gonna close $6 and then $15 AH!!!

[Eurotradr]

Halts killed the rally.

[TheFinalCD]

01/04/2023 14:34:09 TCBP TC BioPharm (Holdings) plc ADS NASDAQ
LUDP
01/04/2023 14:34:09

[Eurotradr]

This POS is a gonner!

[Mrogers23]

$TCBP News

https://finance.yahoo.com/news/tc-biopharm-announces-7-35-130000586.html

[$treet $inatra]

November 1, 2022 vote for 1-50 R/S https://www.otcmarkets.com/filing/html?id=16124542&guid=d6X-kqio8z7qJth

[Awl416]

Volume last night too. News?

[Cameo Brien]

Great update

[resx18]

$TCBP Receives CryoTC® Trademark for Proprietary Cell Freezing Process

https://marketwirenews.com/news-releases/tc-biopharm-receives-cryotc-xae-trademark-for-propri-6509704875493736.html

[Cameo Brien]

GM nuts

[resx18]

Good Morning $TCBP

[Cameo Brien]

Excited for it

[resx18]

Waiting on the $TCBP 3rd phase trial results $

[Cameo Brien]

Awesome

[resx18]

Huge Run to $2.00 $TCBP

[Cameo Brien]

Think so yes sir

[resx18]

Huge MOASS ! $TCBP

[Cameo Brien]

Oh wow

[resx18]

The price target for $TCBP is set to $5.00.



https://www.benzinga.com/analyst-ratings/upgrades/22/03/26322673/benzingas-top-ratings-upgrades-downgrades-for-march-28-2022

[resx18]

EF Hutton initiated coverage on TC BioPharm (Holdings) PLC
TCBP
+20.4%
+ Free Alerts
with a Buy rating. The price target for TC BioPharm (Holdings) is set to $5.00. The stock has a 52-week-high of $3.50 and a 52-week-low of $0.88. At the end of the last trading period, TC BioPharm (Holdings) closed at $1.20.

[Anita Dump]

Good Morning $TCBP

[Tally-ho]

FANTASTIC NEWS OUT TODAY:
TC Biopharm Reports Received Medicines and Healthcare Products Regulatory Agency, Research Ethics Committee Approvals To Initiate Phase 2B/3 Trials For Its Acute Myeloid Leukemia Treatment

Trial enrollment expected to begin during the first half of 2022
EDINBURGH, Scotland, March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that it has received MHRA and Research Ethics Committee approvals to initiate gamma-delta T cell therapy clinical trials of OmnImmune® for the treatment of Acute Myeloid Leukemia (AML).

OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for the treatment of patients suffering from the blood and bone marrow cancer. Phase 2/3 trials will begin enrollment in the first half of 2022 in the UK with expansion into the US following shortly thereafter.

"We are extremely pleased to receive MHRA and Research Ethics approvals, which marks the final step in our protocol submission and commencing through the clinical trial process of our proprietary AML therapy," said Bryan Kobel, CEO of TC BioPharm. "On the heels of announcing our Orphan Drug Dsignation from the FDA, we have now further demonstrated our ability to run parallel processes for clinical trials in both the US and UK/EU. The positive results demonstrated by OmnImmune® in Phase 1b/2a clinical trials are encouraging and bolsters our belief in its potential as an effective therapy for Acute Myeloid Leukemia."

[Cameo Brien]

Hold yer shorts

[resx18]

$TCBP Short Squeeze Report 2022-03-23

https://news.squeezereport.com/short-squeeze/tc-biopharm-holdings-plc-nasdaq-tcbp-short-squeeze-2022-03-23/

[Cameo Brien]

Nice news

[resx18]

$TCBP approved from UK health agency for leukemia therapy trials

https://marketwirenews.com/news-releases/tc-biopharm-receives-mhra-and-research-ethics-commit-6644970306151734.html

[Cameo Brien]

Great week

[resx18]

$TCBP CHART

[resx18]

https://cheddar.com/media/tc-biopharm-goes-public-looks-to-future-of-cancer-covid-19-cell-therapies

[Cameo Brien]

GM sir

[resx18]

Good Morning $TCBP

[Cameo Brien]

LFG $TCBP

[Cameo Brien]

TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta T-cells and owns our manufacturing facility to maintain cost and product quality controls.

[Cameo Brien]

The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b /3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim® in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide.

[Cameo Brien]

TC BioPharm is the leader in developing banked allogeneic gamma-delta T cell therapies, and the first company to conduct ICH compliant phase II/pivotal clinical studies in oncology.

[Cameo Brien]

TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

[Cameo Brien]

Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

[Cameo Brien]

About TC BioPharm, Ltd.
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia.

[Cameo Brien]

OmnImmune® is a frozen and thawed product, now "banked" from donor derived cells. Phase 2/3 trials will begin enrollment in the first quarter of 2022 in the UK with expansion into the US in 2022.

[Cameo Brien]

The trial, for treatment of patients suffering from relapse/refractory Acute Myeloid Leukemia (AML), OmnImmune® comprises GDT cells sourced from healthy donors, expanded and activated in large numbers before being purified and formulated for infusion into patients.

[Cameo Brien]

About OmnImmune®
OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells.

[Cameo Brien]

let er rip